Abstracts tagged "Systemic lupus erythematosus (SLE)"

Abstract Number: 1035 • 2019 ACR/ARP Annual Meeting
Examining the Transcriptional Impact of Liganded ERα in the Inflammatory Milieu of Systemic Lupus Erythematosus
Mara Lennard Richard¹, Melissa Cunningham ², Betty Tsao ³ and Gary Gilkeson ⁴, ¹Medical University of South Carolina, Charleston, SC, ²Medical University of South Carolina, Charleston, ³Division of Rheumatology and Immunology, Department of Medicine, Medical University of South Carolina, Charleston, South Carolina, USA., Charleston, ⁴Division of Rheumatology & Immunology/Ralph H. Johnson VA Medical Center/Medical University of South Carolina, Charleston, SC
Background/Purpose: Systemic lupus erythematosus (SLE) disproportionally affects females (9:1) over males. Despite significant research effort, the exact mechanisms behind this compelling sex bias are undefined.…
Abstract Number: 1395 • 2019 ACR/ARP Annual Meeting
Risk of Immunization to Rituximab in Systemic Autoimmune Diseases and Rheumatoid Arthritis: Frequency and Risk Factors. Analysis of the Efficacy of an Alternative Treatment by Ofatumumab
Alice Combier¹, Gaetane Nocturne ², Julien Henry ³, Rakiba Belkhir ¹, Stephan Pavy ⁴, Clotilde Le Tiec ⁵, Elise Descamps ⁴, Raphaele Seror ⁶ and Xavier Mariette ⁷, ¹Rheumatology Departement - Bicêtre Hospital, Paris, France, ²Center for Immunology of Viral Infections and Autoimmune Diseases, Assistance Publique – Hôpitaux de Paris, Hôpitaux Universitaires Paris-Sud, Le Kremlin-Bicêtre, Université Paris Sud, INSERM, Paris, France., Paris, France, ³Rheumatology Departement - Bicêtre Hospital, Paris, ⁴Rheumatology Departement - Bicètre Hospital, Paris, France, ⁵Pharmacy Departement - Bicètre Hospital, Paris, France, ⁶Hopitaux universitaires Paris Sud, Kremlin-Bicetre, France, ⁷Center for Immunology of Viral Infections and Autoimmune Diseases, Assistance Publique – Hôpitaux de Paris, Hôpitaux Universitaires Paris-Sud, Le Kremlin-Bicêtre, Université Paris Sud, INSERM, Paris, France
Background/Purpose: The most widely used B cell targeted therapies in auto-immune diseases (AID) is Rituximab (RTX), a murine chimeric monoclonal antibody. Among RTX’s side effects,…
Abstract Number: 1592 • 2019 ACR/ARP Annual Meeting
Defining the SLE-Associated Pulmonary Arterial Hypertension Phenotype
Marisa Mizus¹, Jessica Li ¹, Daniel Goldman ² and Michelle Petri ¹, ¹Johns Hopkins University School of Medicine, Baltimore, MD, ²Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Pulmonary arterial hypertension (PAH) is a leading cause of death in SLE patients. Hypocomplementemia, antiphospholipid antibodies, and elevated antibodies to RNP and Ro are…
Abstract Number: 1627 • 2019 ACR/ARP Annual Meeting
Bronchoalveolar Lavage Fluid Analysis and Mortality Risk in Systemic Lupus Erythematosus Patients with Pneumonia and Respiratory Failure
Chien-Chih Lai¹, Yi-Syuan Sun ¹ and Chang-Youh Tsai ², ¹Division of Allergy, Immunology, Rheumatology, Taipei Veterans General Hospital, Taipei, Taiwan (Republic of China), ²Division of Allergy, Immunology & Rheumatology/Taipei Veterans General Hospital, Taipei, Taiwan (Republic of China)
Background/Purpose: To evaluate the pathogens from bronchoalveolar lavage fluid (BALF) and risk factors of mortality in SLE patients with pneumonia and respiratory failure.Methods: Twenty-four SLE…
Abstract Number: 1936 • 2019 ACR/ARP Annual Meeting
The Expression of the Interferon Inducible Gene SERPING1 Is Reduced by Rituximab and Correlates with Clinical Response in Systemic Lupus Erythematosus
Liliana Santos Ribeiro¹, Mariea Parvaz ², Su-Ann Yeoh ² and Michael Ehrenstein ², ¹University College London, London, United Kingdom, ²University College London, London, England, United Kingdom
Background/Purpose: Abnormalities in B cells and the interferon alpha (IFN) pathway have been separately implicated in the pathogenesis of systemic lupus erythematosus (SLE). B cell…
Abstract Number: 2251 • 2019 ACR/ARP Annual Meeting
Understanding Vulnerabilities in Diagnosis and Care of Childhood and Adult-Onset Lupus: A Qualitative Study
Siobhan Case¹, Corine Sinnette ², Courtnie Phillip ², Claire Grosgogeat ³, Karen Costenbader ², Cianna Leatherwood ⁴, Candace Feldman ² and Mary Beth Son ³, ¹Brigham and Women's Hospital and Boston Children's Hospital, Boston, MA, ²Brigham and Women's Hospital, Boston, MA, ³Boston Children's Hospital, Boston, MA, ⁴Kaiser Permanente, San Francisco, CA
Background/Purpose: Systemic lupus erythematosus (SLE) poses complex diagnostic and management challenges, which may differ depending on whether SLE was diagnosed in childhood (cSLE) or in…
Abstract Number: 2532 • 2019 ACR/ARP Annual Meeting
Effect of Treatment on Antiphospholipid Antibodies in SLE
Michelle Petri¹, Laurence Magder ² and Daniel Goldman ³, ¹Johns Hopkins University School of Medicine, Baltimore, MD, ²University of Maryland School of Medicine, Baltimore, MD, ³Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Unlike primary antiphospholipid syndrome patients, most SLE patients with antiphospholipid antibodies are on one or more treatments for their SLE that might affect levels…
Abstract Number: 2566 • 2019 ACR/ARP Annual Meeting
Polypharmacy and Potentially Inappropriate Medication Use in Young versus Older Adults with SLE
Dale Seguin¹, Christine Peschken ², Casandra Dolovich ¹, Ruby Grymonpre ¹, Phil St. John ¹ and Annaliese Tisseverasinghe ¹, ¹University of Manitoba, Winnipeg, MB, Canada, ²University of Manitoba, Winnipeg, Canada
Background/Purpose: Polypharmacy, typically defined as ≥ 5 medications (meds), is a strong risk factor for adverse clinical outcomes, including delirium, falls, hospitalization, and death, especially…
Abstract Number: 2814 • 2019 ACR/ARP Annual Meeting
Methionine Commits Immunometabolism and Epigenetic Regulation of BACH2 Loci in B Cells, Resulting in Biases Toward Plasmablast Differentiation in the Pathogenesis of SLE
Mingzeng Zhang¹, Shigeru Iwata ¹, Maiko Hajime ¹, Naoaki Ohkubo ¹, Yasuyuki Todoroki ², Hiroko Miyata ², Jie Fan ², Shingo Nakayamada ¹, Kaoru Yamagata ¹ and Yoshiya Tanaka ³, ¹The First Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan, Kitakyushu, Japan, ²The First Department of Internal Medicine, University of Occupational & Environmental Health Kitakyushu, Japan, Kitakyushu, Japan, ³University of Occupational and Environmental Health Japan, Kitakyushu, Japan
Background/Purpose: Amino acids play an important role in various metabolic processes. However, the role of amino acid metabolism in the regulation of human B cell…
Abstract Number: 85 • 2019 ACR/ARP Annual Meeting
Selective Inhibition of the Immunoproteasome with KZR-616 Blocks Multiple Cell Signaling Pathways, Plasma Cell Signatures and Myeloid Cell Associated Damage in the NZB/W Lupus Nephritis Model
Tony Muchamuel¹, Janet Anderl ¹, R Andrea Fan ¹, Henry Johnson ¹, Dustin McMinn ¹ and Christopher Kirk ¹, ¹Kezar Life Sciences, South San Francisco, CA
Background/Purpose: The immunoproteasome is a distinct class of proteasome found predominantly in immune effector cells and has been shown to play a distinct role in…
Abstract Number: 661 • 2019 ACR/ARP Annual Meeting
Association of Serum and Urine Levels of TWEAK, MCP-1 and NGAL with Disease Activity in Systemic Lupus Erythematosus
SAFAK MIRIOGLU ¹, SUZAN CINAR ², Halil Yazici ³, Ahmet Gül ⁴, Lale Öcal ⁴, Murat Inanc ⁴ and Bahar Artim-Esen⁴, ¹Istanbul University, Istanbul Faculty of Medicine, Department of Internal Medicine, ISTANBUL, Turkey, ²Istanbul University,Department of Immunology, Institute of Experimental Medicine, ISTANBUL, Turkey, ³Istanbul University, Istanbul Faculty of Medicine, Department of Internal Medicine, Division of Nephrology, Istanbul, Turkey, ⁴Istanbul University, Istanbul Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey
Background/Purpose: TWEAK, MCP-1 and NGAL, mediators in pathogenesis of systemic lupus erythematosus (SLE), are proinflammatory cytokines/chemokines that are thought as potential biomarkers reflecting disease activity.…
Abstract Number: 883 • 2019 ACR/ARP Annual Meeting
B Cell-specific MyD88 Regulates Pathology After Disease Onset in Murine Lupus
Jeremy Tilstra¹, Minjung Kim ¹, Claire Leibler ¹ and Mark Shlomchik ¹, ¹University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Systemic lupus erythematosus (SLE) is a complex autoimmune disease defined by immune dysregulation, antibody formation, followed by end-organ damage. MyD88 is a central immune…
Abstract Number: 1038 • 2019 ACR/ARP Annual Meeting
Distinct Cell-bound Complement Activation Signatures Are Observed in Patients with Systemic Lupus Erythematosus
Rebecca Schriefer ¹, Gabriel Arguelles ¹, John Atkinson ¹, Dennis Hourcade ¹ and Alfred Kim¹, ¹Washington University School of Medicine, Saint Louis, MO
Background/Purpose: Cell-bound complement activation products (CB-CAPs) have previously been shown to associate with SLE disease activity, but only a small fraction of total CB-CAPs has…
Abstract Number: 1469 • 2019 ACR/ARP Annual Meeting
New 2019 SLE EULAR/ACR Classification Criteria for SLE Are Valuable for Distinguishing Patients with SLE from Patients with pSS in Daily Practice
Florence Assan¹, Raphaele Seror ², Gaetane Nocturne ³ and Xavier Mariette ⁴, ¹Université Paris Sud, Hôpitaux Universitaires Paris-Sud, AP-HP, INSERM UMR 1184, Le Kremlin-Bicêtre, France, ²Hopitaux universitaires Paris Sud, Kremlin-Bicetre, France, ³Center for Immunology of Viral Infections and Autoimmune Diseases, Assistance Publique – Hôpitaux de Paris, Hôpitaux Universitaires Paris-Sud, Le Kremlin-Bicêtre, Université Paris Sud, INSERM, Paris, France., Paris, France, ⁴Center for Immunology of Viral Infections and Autoimmune Diseases, Assistance Publique – Hôpitaux de Paris, Hôpitaux Universitaires Paris-Sud, Le Kremlin-Bicêtre, Université Paris Sud, INSERM, Paris, France
Background/Purpose: The new 2019 SLE EULAR/ACR Classification Criteria for Systemic lupus erythematosus (SLE) have been developed to find a better equilibrium between specificity and sensitivity…
Abstract Number: 1596 • 2019 ACR/ARP Annual Meeting
Assessing the Validity of QRISK3 at Predicting Cardiovascular Events in Systemic Lupus Erythematosus Patients
Lisa Zhu¹, Manpreet Singh ¹, Sonia Lele ¹, Mei Liang ², Lori Sahakian ¹, Jennifer Grossman ¹ and Maureen McMahon ¹, ¹UCLA David Geffen School of Medicine, Los Angeles, CA, ²Williams College, Williamstown, MA
Background/Purpose: It has been well established that patients with systemic lupus erythematosus (SLE) have an increased risk of developing cardiovascular disease (CVD). Traditional CVD risk…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].